Ellis Levine

MD
Medical Oncology
2022 Buffalo Spree Top Docs badge

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Bladder Cancer Breast Cancer Prostate Cancer Testicular Cancer

Special Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program

Background

Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA

Residency:

  • University of Minnesota, Minneapolis, MN

Fellowship:

  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2018 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Learn More
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More

Clinical Trials

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Learn More
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Breast cancer at 32: Sheila's story Breast Cancer in Young Women: Family History Is the Best Indicator of Risk Can Breast Cancer Return After a Double Mastectomy? Prostate Cancer Survivor: Denny's Story Breast Cancer in Men: Owen’s Story What Happens If My Cancer Treatment Stops Working? How Research Saved My Life Detours and Delays, Then a New Route to Happiness What Happens When Pregnancy and Cancer Collide?

Featured on Cancer Talk

Breast cancer at 32: Sheila's story
Breast Cancer in Young Women: Family History Is the Best Indicator of Risk
Can Breast Cancer Return After a Double Mastectomy?

Showing all3 of 9

Publications

Full Publications list on PubMed

Eastham JA, Heller G, Hillman DW, Hahn OM, Parsons JK, Mohler JL, Small EJ, Morris M. Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). J Urol. 2021 Aug;206(2):319-324. doi: 10.1097/JU.0000000000001716. Epub 2021 Mar 29. PubMed PMID: 33780276; PubMed Central PMCID: PMC8273099.

Skolnik J, Hall D, Barkauskas DA, Moorthy G, Larson TR, Fox E, Weigel BJ, Berg SL, Reid JM. Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. Cancer Chemother Pharmacol. 2021 Aug;88(2):359-365. doi: 10.1007/s00280-021-04295-1. Epub 2021 May 22. PubMed PMID: 34023919; PubMed Central PMCID: PMC8653953.

Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarz RL, Smith KL, Brown-Glaberman UA, Winn JS, Faller BA, Onitilo AA, Burkard ME, Budd GT, Levine EG, Royce ME, Kaufman PA, Thomas A, Trepel JB, Wolff AC, Sparano JA. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6. PubMed PMID: 34357781; PubMed Central PMCID: PMC8478386.

Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 Nov 23;5(22):4691-4700. doi: 10.1182/bloodadvances.2021004813. PubMed PMID: 34492682.

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 1;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 6. PubMed PMID: 34559902; PubMed Central PMCID: PMC8713771.